Read publication

In this issue:

  • Singapore Association of Pharmaceutical Industries (SAPI) Code's Guidance On Sponsorship of Third Party Events Effective from January 2019
  • Health Sciences Authority (HSA) Introduces "Doand-Tell" Approach for Minor Variations of Therapeutic Products
  • HSA Makes Amendments to Categorisation of PostApproval Variations (MAV1 and MIV)
  • HSA Makes Amendments to Guidance on Therapeutic Product Registration
Explore More Insight